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1. Introduction 
Over the last decade, research has implicated a group of molecular chaperones termed 
Heat Shock Proteins (HSPs) as major contributors to cancer progression and the 
development of chemo-resistance. HSPs were initially discovered as a group of proteins 
that were strongly induced in response to heat shock and other cellular stresses. Under 
non-stress conditions, they have a wide variety of roles within many sub-cellular 
compartments where they facilitate protein folding, prevent protein unfolding and assist 
protein transport across membranes. Due to their roles in maintaining protein 
conformation, HSPs are vital when other cellular proteins start to unfold due to cellular 
stress such as high temperature, exposure to cytotoxic chemicals or oxidative stress and 
are up-regulated rapidly in these situations (Ciocca and Calderwood, 2005). Under these 
stressful conditions, HSPs prevent protein aggregation, stabilise cell membranes and 
inhibit many of the key steps in cell death pathways (Beere & Green, 2001), thereby 
enabling cell survival in conditions that would otherwise be lethal. Importantly, in normal 
cells, once the stress has passed, HSP levels return to baseline and these proteins return to 
their regular house-keeping duties. However, a growing body of research shows that in 
tumour cells, including Chronic Lymphocytic Leukaemia (CLL) cells, HSPs remain 
elevated and may contribute to prolonged tumour cell survival via several mechanisms 
that remain to be fully revealed.  
Human HSPs were originally identified as stress-induced proteins and were traditionally 
split into five families based on their molecular weight. These five families were the HSP27, 
HSP60, HSP90, HSP70 and HSP110 families. However, the sequencing of the human 
genome led to the identification of additional members of well established HSP families. 
Furthermore, the expansion of these HSP families resulted in many HSPs being referred to 
by several different names. Therefore, attempts to draw comparisons between studies 
examining specific HSPs has proved challenging. Consequently, Kampinga et al. (2009) 
recently introduced guidelines for the nomenclature of human HSPs which ensures that the 
genes and proteins are named in a consistent manner (Table 1). Readers are referred to 
Kampinga et al. (2009) for a complete listing of human HSP nomenclature. This chapter will 
focus on the involvement of the major HSPs, HSPB1 (Hsp27) HSPA1A (Hsp72) and HSPC1 
(Hsp90) in the development and progression of CLL. 
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Gene Name 
New Protein 
Name 
Old Names 
HSPB1 HSPB1 Hsp27, Hsp28; Hsp25 
DNAJB1 DNAJB1 Hsp40 
HSPD1 HSPD1 Hsp60 
HSPA8 HSPA8 HSC70, Hsp71, Hsp73 
HSPA9 HSPA9 Mortalin, mtHsp70, GRP75 
HSPA1A HSPA1A Hsp72, Hsp70-1, HSPA1 
HSPC1 HSPC1 Hsp90, HSP90A, Hsp89, HSP90AA 
HSPH2 HSPH2 Hsp110 
(Adapted from Kampinga et al. 2009) 
Table 1. New nomenclature for human HSPs referred to in this chapter  
The up-regulation of a number of HSPs in response to stress stimuli is regulated by the 
transcription factor Heat Shock Factor-1 (HSF1) (Wu, 1995). Under non-stress conditions, 
members of the DNAJ and HSPA families along with HSPC1 are bound to monomeric 
HSF1 within the cytosol. However, under stress conditions these HSPs dissociate from 
HSF1 and bind misfolded proteins, suggesting that these HSPs have a higher affinity for 
misfolded proteins compared to HSF1. As a consequence HSF1 trimerises and migrates to 
the nucleus where, in this state, it has a high binding affinity for cis-acting DNA sequence 
elements known as Heat Shock Elements (HSEs) in the promoter region of the HSP genes 
resulting in transcription of HSP genes (Sorger , 1991). Once the stress is discontinued, the 
trimeric forms of HSF1 dissociate from the HSEs and are converted back to HSF1 
monomers with the inability to bind DNA. It is believed that the increase in HSPs within 
the cell following the heat shock response are themselves negative regulators of HSF, 
binding to HSF and preventing further trimerisation (Wu, 1995). HSPC1 has been shown 
to be a negative regulator of HSF1, as immunodepletion of HSPC1 results in enhanced 
HSF1 activity (Zou et al. 1998). 
2. HSPs in cancer 
The potential importance of HSPs in tumour biology is clear when considering their 
activities in light of the Hanahan & Weinberg concept of the hallmarks of cancer (Hanahan 
& Weinberg 2000; Hanahan & Weinberg 2011), where the development of a malignant 
phenotype requires six modifications:  
 self-sufficiency with respect to growth signals 
 limitless replicative potential 
 insensitivity to anti-growth signals 
 sustained angiogenesis 
 capacity for tissue invasion and metastasis 
 evasion of apoptosis 
HSPs have the potential to contribute to each of these modifications, and three HSPs 
(HSPB1, HSPA1A and HSPC1) can be shown to influence at least two of these modifications. 
Not surprisingly it is these three HSPs that feature most in tumour studies.  
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HSPB1 belongs to the family of small heat shock proteins. Besides its role as an ATP-
independent molecular chaperone, it is involved in the regulation of cell differentiation, the 
acquisition of thermotolerance and the inhibition of apoptosis and cell senescence. HSPB1 is 
up-regulated in response to a wide variety of stress stimuli such as oxidative stress, 
exposure to anti-cancer agents and radiation (Lanneau et al. 2008). As a molecular 
chaperone, HSPB1 prevents protein aggregation and stabilises partially denatured proteins 
ensuring refolding by other chaperones such as HSPA1A and HSPC1.  
HSPA1A is the main inducible member of the HSPA family and is not normally present in 
significant concentrations in non-stressed normal cells. HSPA1A mainly exists as a dimer, 
and similarly to HSPB1 is up-regulated in response to a wide variety of stress stimuli and 
promotes cell survival. HSPA1A has a high affinity for hydrophobic amino acids and will 
rapidly bind to partially denatured proteins in preparation for refolding or disposal. 
HSPC1 is the most abundant member of the HSPC family, and is constitutively expressed in 
all eukaryotic cells where it binds a specific set of ‘client proteins’ including steroid 
receptors, non-receptor tyrosine kinases and cyclin-dependent kinases (McLaughlin et al. 
2002). HSPC1 operates as part of a multimeric chaperone complex which includes members 
of the HSPA and DNAJ families, along with many other ‘co-chaperones’ and 
immunophillins (Holzbeierlein et al. 2010). It exists as a dimer, consisting of three major 
domains per monomer; A C-terminal homodimerisation domain, a middle ATP-hydrolysis-
regulating domain, and an N-terminal, ATP binding domain (Krukenberg et al. 2011).   
At one time HSPs were thought to be solely intracellular proteins (iHSPs). However certain 
HSPs have been found to be released from viable cells into the extracellular milieu (eHSPs) 
(Hightower & Guidon, 1989; Hunter-Lavin et al. 2004) and have also been found expressed 
on the tumour cell surface (sHSPs). The exact mechanism involved in the transport of these 
HSPs from the cytosol to the cell surface and extracellular environment have not been fully 
determined, but evidence suggests that HSPs may employ a number of methods including 
lipid-raft transport (Hunter-Lavin et al. 2004; Gastpar et al 2005; Vega et al. 2008), exosomal 
transport (Clayton et al. 2005) and ABC transporters (Mambula & Calderwood 2006). 
Regardless of their route of exit, sHSPs and eHSPs have critical roles in a variety of 
processes ranging from cell invasion and metastasis to immunomodulation.  
3. Intracellular HSPs  
3.1 Intracellular HSPs and prognosis 
The up-regulation of HSPs inside cancer cells compared to normal cells has been well 
documented and has led to numerous studies investigating their prognostic and therapeutic 
potential (Calderwood et al. 2006; Ciocca et al. 2005; Sherman & Multhoff. 2007). In many cases 
high levels of HSPs have been found to be advantageous to the cancer cell, which is hardly 
surprising when considering that HSPB1, HSPA1A and HSPC1 are all anti-apoptotic factors, 
and would suggest that these proteins should have prognostic potential. However, although 
elevated HSPA1A, HSPB1, and HSPC1 are associated with poor prognosis in leukaemia, this 
pattern is not repeated in other cancers (Table 2) (Jaattela, 1999; Ciocca & Calderwood, 2005). 
In a minority of cancer types, the over-expression of HSPs appears to correlate with a positive 
prognosis for the patient (Kawanishi et al. 1999; Sagol et al. 2002; Santarosa et al. 1997) and at 
present it is still unclear as to how HSP expression may influence cancer progression.  
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Increased levels of HSPB1 have been documented in various cancers including breast, liver 
and prostate (Cornford et al. 2000; Romani et al. 2007; Vargas-Roig et al. 1997) and high 
levels have been found to correlate with poor prognosis (Duval et al. 2006; Thomas et al. 
2005). However, there are contradictions within the literature; In breast cancer, for example, 
increased levels of HSPB1 have been associated with prolonged survival in oestrogen 
receptor-negative cases (Love & King, 1994). Low levels of HSPB1 in ovarian cancer have 
also been found to correlate with decreased survival (Geisler et al. 2004). However, these 
contradictions may be attributed to HSPB1, (synonymous with p24 and p29), being an 
oestrogen-regulated protein (Adams & McGuire, 1985; Ciocca & Luque, 1991). 
Increases in HSPA1A have been observed in breast cancer (Tauchi et al. 1991), colorectal 
cancer (Milicevic et al. 2007; Shotar, 2005), kidney cancer (Ramp et al. 2007) and leukaemia 
(Chant et al. 1995; Thomas et al. 2005). Additionally, elevated HSPA1A has been associated 
with resistance to cancer therapy and/or poor prognosis for the patient (Thomas et al. 2005; 
Vargas-Roig et al. 1998). However, the relationship between the presence of HSPs and 
prognosis cannot be extrapolated to all cancers, as high intracellular HSPA1A expression 
has been correlated with a positive prognosis in oesophageal (Kawanishi et al. 1999), 
pancreatic (Sagol et al. 2002) and renal cancer (Santarosa et al. 1997). 
HSPC1 levels are elevated in a number of cancer types including oesophageal squamous cell 
carcinoma (Wu et al. 2009), invasive breast carcinoma (Zagouri et al. 2010) and leukaemia 
(Thomas et al. 2005). Furthermore, in some cases, elevated HSPC1 levels have been 
associated with decreased survival and adverse karyotypes (Pick et al. 2007; Thomas et al. 
2005). 
 
Cancer type HSPA1A HSPB1 HSPC1 
Breast Poor Variable n/d 
Endometrial Poor n/d Good 
Kidney Good n/d n/d 
Leukaemia Poor Poor Poor 
Lung n/d n/d n/d 
Osteosarcoma Good Poor Variable 
Ovary n/d Poor n/d 
(Adapted from Jaattela, (1999) and Ciocca & Calderwood, (2005)) 
Table 2. Association of HSP over-expression with prognosis 
It is clear that different HSPs have distinct roles in normal cells and therefore it is not 
inconceivable that they may also have a variety of roles in tumour development. Indeed, the 
over-expression of one particular HSP within a tumour cell does not necessarily signify 
elevated levels of other HSPs within the same patient; In CLL particularly, HSPB1, HSPA1A 
and HSPC1 increases have been observed amongst patients but not necessarily 
simultaneously (Dempsey et al. 2010a). Similarly there is little correlation between the 
expression of HSPB1, HSPA1A and HSPC1 in prostate cancer (Cornford et al. 2000) or AML 
(Thomas et al. 2005). It is therefore imperative to understand the individual roles of these 
proteins in cancer development by studying them together within a specific sample but also 
considering them as distinct entities. 
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3.2 Intracellular HSPs and resistance to apoptosis 
Mechanistic investigations have shown that HSPB1 interferes with the apoptotic pathway in 
several ways including the prevention of cytochrome c and Smac/DIABLO release from the 
mitochondria (Chauhan et al. 2003a; Paul et al. 2002) and direct interaction with cytochrome 
c (Garrido et al. 2001; LeBlanc, 2003; Samali et al. 2001) and Daxx (Charrette et al. 2000) 
thereby inhibiting their function. There is clear evidence that HSPB1 levels correlate with 
chemo-resistance (Schepers et al. 2005; Vargas-Roig et al. 1998). Studies designed to explore 
the role of HSPB1 in the development of chemo-resistance have utilised various techniques 
including siRNA and gene transfection. Depletion of HSPB1 has been shown to overcome 
resistance to drug-induced apoptosis (Chauhan et al. 2003b) while transfection of full-length 
HSPB1 into cancer cells confers resistance to Cisplatin and Doxorubicin (Richards et al. 
1996).  
HSPA1A is involved in carcinogenesis at many different stages from the enhancement of 
activity of many different oncogenes and inhibition of tumour suppressor genes such as p53 
(Yaglom et al. 2007), to promoting the survival of tumour cells through inhibition of 
apoptosis (Khaleque et al. 2005; Nylandsted et al. 2000). Similarly to HSPB1, HSPA1A 
interacts with several key proteins in cell death pathways (Beere & Green, 2001). Direct 
interaction with APAF-1 and mutated p53 (Iwaya et al. 1995; Lehman et al. 1991) has been 
documented as well as direct inhibition of procaspases. Several studies have shown that 
depletion of HSPA1A results in increased sensitivity to chemotherapeutic drugs (Zhao & 
Shen, 2005) and ultimately apoptosis of various cell lines including breast, colon and 
prostate (Nylandsted et al. 2000), highlighting the importance of this protein for cell 
survival.  
A wide variety of client proteins are held by HSPC1 in both tumour and non-tumour cells, 
and as a result it is involved in several vital signalling pathways including PI3K/Akt, 
Erk1/2, JNK and NFκB pathways. It is the chaperoning of a variety of oncoproteins such as 
mutant B-Raf (Grbovic et al. 2006), Bcr/Abl (An et al. 2000) and mutant p53 (Lin et al. 2008), 
as well as the signalling pathway components, that has sparked interest into HSPC1’s 
potential role in tumour development and progression. HSPC1 also cooperates with 
HSPA1A in inhibiting apoptosome formation. Furthermore, HSPC1 interferes with death 
receptor mediated apoptosis by stabilising the anti-apoptotic protein Receptor Interacting 
Protein (RIP) thereby promoting cell survival.  
Clearly HSPB1, HSPA1A and HSPC1 interfere with apoptotic signalling at multiple points 
(Figure 1). 
4. Extracellular HSPs 
4.1 Extracellular HSPs in immunomodulation 
As a consequence of their molecular chaperoning role, HSPs exit the cell bound to a wide 
variety of antigenic peptides. These extracellular HSP-peptide complexes bind to surface 
receptors on Antigen Presenting Cells (APCs) in a process termed cross-presentation 
(Bolhassani & Rafati, 2008). During the process of necrosis, when cell stress is highest and the 
cellular components leak out of the cell, these HSP-peptide complexes are abundant and can 
signal stress to local APCs, which in-turn can induce a Cytotoxic T-Lymphocyte (CTL) 
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Fig. 1. Regulation of the Death Receptor and Mitochondrial Apoptosis Pathways by HSPs 
(Taken from Dempsey, 2009). Two main arrows represent the Death Receptor-mediated- and 
mitochondrial- apoptosis pathways. HSPB1 inhibits apoptosis by directly interacting with 
Daxx, and sequestering cytochrome c released from the mitochondria. HSPD1 has been shown 
to directly promote the proteolytic maturation of caspase-3, thereby displaying a pro-apoptotic 
role. HSPA1A inhibits apoptosis by inhibiting the activation of protein kinases involved in 
signal transduction pathways (e.g. JNK), binding to AIF thereby neutralising its effects and 
binding to Apaf-1 resulting in inhibition of apoptosome formation. HSPC1 has been shown to 
stabilise the anti-apoptotic protein, RIP and has also been shown to work synergistically with 
HSPA1A to inhibit apoptosome formation. Apoptosis induced by Death Receptors also results 
in activation of the mitochondrial pathway via cleavage of the pro-apoptotic protein Bid. A 
minus sign indicates negative regulation while a positive sign indicates positive regulation.  
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response. Similarly, viable tumour cells with high HSP levels may also actively release HSP-
peptide complexes into the surrounding environment. Research investigating the HSP-APC 
interactions has revealed a number of APC receptors capable of binding HSPs; Scavenger 
receptors (SRs), Toll-like receptors (TLRs), CD40, CD14 and CD91 (Calderwood et al. 2007; 
Basu et al. 2001) allow HSP-peptide complexes to interact with a number of different 
immune cell types including Dendritic cells, Macrophages, Monocytes and NK-cells 
(Murshid et al. 2008).  
The binding of HSPA1A-peptide complexes to the SR LOX-1 on Dendritic cells, for 
example, results in the internalisation of the HSP-peptide complex (Arnold-Schild et al. 
1999) via the phagocytic pathway, and re-presentation of the antigenic peptide on MHC-I 
on the Dendritic cell surface. Work by Kurotaki et al. (2007) has revealed the significance 
of HSPs in this antigen cross presentation process; Dendritic cells were found to bind and 
internalise HSPC1-peptide complexes and generate a T-cell response, while unconjugated 
peptide was unable to stimulate this same response. In order for APCs to effectively 
activate a T-cell response, they must undergo maturation to express appropriate co-
stimulatory molecules. Indeed, HSPA1A has been shown to stimulate the expression of 
CD40, CD83 and CD86 on Dendritic cells (Bausero et al. 2005; Kuppner et al. 2001). 
Additionally, the expression and release of pro-inflammatory cytokines such as IL-1ǃ, IL-
6, IL-12 and TNF-ǂ is stimulated by HSPs (Asea et al. 2000; Baretto et al. 2003; Todryk et 
al. 1999). There appears to be a positive feedback system in which APC-released pro-
inflammatory cytokines augment transcription and release of HSPA1A from tumour cells 
(Baretto et al. 2003). The immunomodulatory properties of extracellular HSPs have 
identified them as a potential ‘danger signal’, released by cells in order to signal stress to 
the immune system (Todryk et al. 2000; Williams & Ireland 2008). Furthermore, as HSP-
peptide complexes can induce both innate and adaptive immunity, they have become 
attractive candidates for immunotherapy protocols. Clinical trials have investigated the 
use of HSP-based vaccines on solid tumours and lymphomas but results have been 
inconclusive (Murshid et al. 2008). The technique involves isolating and purifying HSP 
from the patient’s tumour cells and re-applying this as a vaccine in order to stimulate an 
immune response. A critical advantage of using such treatments is that, by exploiting the 
chaperoning ability of HSPs, a broad range of tumour-specific peptides, unique to that 
specific tumour will be targeted.  
4.2 Distinct roles of membrane bound HSPs 
A number of HSPs are also present on the tumour cell surface, and have distinct roles 
dependent on the specific HSP. HSPA1A in particular has been found embedded in the cell 
membrane of a variety of tumour cell types (Kleinjung et al. 2003; Pfister et al. 2007) and 
work from our lab has shown sHSPA1A on CD5+/CD19+ cells from CLL patients 
(Dempsey et al. 2010a). To date, it appears that the membrane localisation of HSPA1A is 
specific to tumour cells and has attracted much attention as a potential therapeutic target 
(Gehrmann et al. 2008; Krause et al. 2004), the implications of which will be discussed later 
in this chapter.  
sHSPA1A acts a recognition structure for activated NK-cells (Gehrmann et al. 2003; Gross et 
al. 2003; Multhoff et al. 1999) and is therefore detrimental for the tumour cell. The region of 
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the HSPA1A molecule exposed to the extracellular milieu of tumours has been identified as 
the 14-mer peptide TKDNNLLGRFELSG (TKD peptide) (Multhoff et al. 2001). The 
stimulation of NK cells using the TKD peptide and low dose IL-2 results in up-regulation of 
CD94/CD56 on NK cells and initiates NK-cell killing of sHSPA1A+ tumour cells (Gross et 
al. 2003; Gross et al. 2008; Multhoff et al. 1999). Interestingly, purified (perforin-free) 
granzyme B from NK-cells was shown to bind to HSPA1A and result in granzyme B 
internalisation into sHSPA1A+ tumour cells (Gross et al. 2003). Stimulation of NK-cells was 
also observed following incubation with sHSPA1A+ tumour-cell derived exosomes (Gastpar 
et al. 2005). Wei et al. (1996) demonstrated that sHSPA1A is also a target for ǅǄT-cells. 
Furthermore, the induced in-vivo expression of sHSPA1A on tumour cells increases their 
immunogenicity, resulting in both a CTL-mediated and NK-cell mediated response and 
rejection of the tumour (Chen et al. 2002a). The expression of sHSPA1A, therefore, 
overcomes many of the characteristics that tumour cells develop to evade immune 
recognition, including down-regulation of MHC molecules, and down-regulation of co-
stimulatory and adhesion molecules (Bausero et al, 2005; Chen et al. 2002a). The literature to 
date, suggests that the cellular location of HSPA1A is crucial in determining disease 
outcome as iHSPA1A is advantageous to the tumour, while sHSPA1A appears to be 
detrimental. 
In contrast to this theory, the small number of studies to date, investigating the presence of 
sHSPA1A in primary cells from leukaemic patients suggest that its presence may in fact be 
detrimental for the patient. The study by Gehrmann et al. (2003) demonstrated that although 
sHSPA1A acted as a recognition structure for NK cells, sHSPA1A expression could be 
correlated with unfavourable or intermediate cytogenetics. Similarly, sHSPA1A levels were 
found to be higher in AML patients with treatment-refractory disease and active disease 
than patients in complete remission, suggesting a correlation with poor prognosis (Steiner et 
al. 2006). Furthermore, AML patients continuing to express moderately high levels of 
sHSPA1A after achieving remission were shown to have a shorter relapse-free survival time 
than remission patients with lower levels of sHSPA1A (Steiner et al. 2006). No correlation 
between sHSPA1A expression and stage of AML or resistance to chemotherapy could be 
determined by Steiner et al. (2006), suggesting that surface localisation of HSPA1A cannot 
be investigated in isolation. Schilling et al. (2007) demonstrated co-expression of HSPA1A 
with phosphatidylserine (PS) on the surface of hypoxic tumour cell lines. Additionally, 
exogenously added HSPA1A was shown to bind to PS on the cell surface and enhance the 
response to radiation. The results indicate that the radiotherapy-resistance observed in 
many hypoxic tumours may be overcome by prior treatment with HSPA1A.  
In addition to HSPA1A, cell surface expression of HSPC1 and HSPB1 on tumour cells has 
been reported (Becker et al. 2004; Brameshuber et al. 2010; Ferrarini et al. 1992; Shin et al. 
2003). sHSPC1 has been shown to be involved in tissue invasion and metastasis (Eustace et 
al. 2004), while the role of sHSPB1 is still unclear. Indeed, inhibiting cell surface expression 
of HSPC1, both in-vitro and in-vivo, reduces cell motility and invasiveness (Eustace et al. 
2004; Tsutsumi et al. 2008). Work by Sidera et al. (2008) proposes that in some cancer cell 
types, sHSPC1 interacts with and activates HER-2, resulting in homodimerisation with 
ErbB-3, signal transduction pathway activation and ultimately actin rearrangement. 
Secretion of HSPC1 in exosomes has also been discovered, and has been shown to contribute 
to cancer cell invasiveness (McCready et al. 2010).  
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It is clear that extracellular HSPs have critical roles in tumour development and immune 
responses and we therefore suggest that mechanistic investigations of tumour biology 
should include analysis of extracellular, as well as intracellular, HSPs. 
5. HSPs in leukaemia 
Although a large amount of data exists regarding the expression of HSPs in cancer, the 
majority of studies have focused on solid tumours. Cells within a solid tumour mass are 
subjected to high levels of stress; the tumour microenvironment is often hypoxic and 
nutrient deficient and there may be infiltration by large numbers of immune cells. Therefore 
it is not surprising that HSP levels are elevated in many solid tumour types. Leukaemia cells 
however, are not subjected to these same stresses and as a result may not necessarily show 
elevated levels of HSPs.  
Of the limited number of studies investigating HSP expression in leukaemia, a number have 
focused on correlating HSP expression with prognosis and clinical outcome, while others 
have directed research towards HSP expression and susceptibility to apoptosis. One study 
by Thomas et al. (2005) explored the expression of intracellular HSPB1, HSPD1, HSPA1A, 
HSPC1 and HSPH2 in both peripheral blood and bone marrow from patients with Acute 
Myeloid Leukaemia (AML). It was noted that complete remission rates were higher in 
patients with lower HSP expression and that overall survival was also significantly longer in 
these patients. Similarly, overall survival was found to be significantly greater in 
Myelodysplastic Syndrome (MDS) patients with lower HSPB1, HSPD1, HSPC1 and HSPH2 
expression (Duval et al. 2006). A study exploring the expression of surface HSPA1A 
(sHSPA1A) in bone marrow aspirates from AML patients demonstrated that patients in 
complete remission express significantly lower levels of sHSPA1A when compared to 
patients with active AML (Steiner et al. 2006). Taken together these results suggest that 
higher levels of HSP expression both internally and on the surface of the leukaemic cell are 
advantageous to the cancer cell and therefore an adverse factor for the patient. This is in 
contrast to studies that have demonstrated the involvement of sHSPA1A in immune 
recognition and tumour regression (Chen et al. 2002; Multhoff et al. 1999; Gross et al. 2003; 
Gross et al. 2008). 
HSP expression in AML and MDS has also been found to correlate with expression of the 
myeloblast surface antigen CD34, a well established poor prognostic factor (Duval et al. 
2006; Thomas et al. 2005). Moreover, AML and MDS patients with intermediate or 
unfavourable karyotypes display a higher level of HSP expression than patients with 
favourable karyotypes. In contrast, Steiner et al. (2006) did not establish a correlation 
between sHSPA1A expression and cytogenetic risk group or FAB subtype. A study into 
expression of HSPD1, HSPA1A, HSPA8 (constitutive and heat-inducible forms) and HSPC1 
in AML cells showed a heterogeneous expression of all three HSPs and no correlation was 
found between this extensive range of HSP expression and clinical outcome (Chant et al. 
1995). However, a more recent study by the same group demonstrated that although AML 
cells show a broad range of HSPA1A expression, this expression correlates with 
susceptibility to apoptosis (Chant et al. 1996). Surprisingly, the correlation between HSPA1A 
expression and apoptosis was positive, indicating that cells with higher levels of the protein 
are more susceptible to apoptosis. This finding is contradictory to the theory that HSPA1A 
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protects cells from apoptosis. In spite of this correlation between HSPA1A and apoptosis, 
none was found between expression of HSPC1 and susceptibility to apoptosis. In contrast, 
levels of HSPA1A in MDS did not correlate with either pro- or anti-apoptotic protein levels 
(Duval et al. 2006).  However, levels of HSPB1, HSPD1, HSPC1 and HSPH2 negatively 
correlated with the expression of the pro-apoptotic proteins Bad and Bak, while correlating 
positively with the anti-apoptotic proteins Bcl-2 and Bcl-Xl.  
Research into acute lymphoblastic leukaemia (ALL) has shown decreased expression of 
HSPA1A and HSPB1 in bone marrow aspirates from patients who achieved complete 
remission when compared to those patients who did not achieve complete remission 
(Campos et al. 1999). Additionally, ALL cells displaying the Bcr/Abl fusion protein 
contained high levels of HSPA1A (Nimmanapalli et al. 2002). Further studies have 
demonstrated that HSPA1A contributes to the Bcr-Abl–mediated resistance to apoptosis by 
chemotherapeutic agents such as etoposide. Moreover, down-regulation of HSPA1A can 
sensitise these Bcr/Abl ALL cells to cytotoxic drugs (Guo et al. 2005). The Bcr/Abl fusion 
protein was shown to be a client protein of HSPC1. Furthermore, inhibition of HSPC1, but 
not HSPA1A, in myeloid cells was found to result in degradation of Bcr/Abl (Peng et al. 
2007). 
6. HSPs in chronic lymphocytic leukaemia 
An extensive study by our group analysed the levels of HSPB1, HSPA1A and HSPC1 in 
CD5+/CD19+ and CD5-/CD19+ cells from CLL patients and normal lymphocytes from 
control subjects (Dempsey et al. 2010a). At first glance, it would appear that levels of both 
iHSPC1 and iHSPB1 are significantly higher in CLL patients overall than normal age-
matched control subjects. An initial analysis of our data would also support the 
hypothesis that elevated intracellular HSP leads to tumour cells being resistant to 
apoptosis (Khaleque et al. 2005; Nylandsted et al. 2000; Thomas et al. 2005; Vargas-Roig et 
al. 1998); Caspase-3, a marker of apoptosis, was found to be lower in CLL patients 
compared to age-matched control subjects, while levels of iHSPB1 and iHSPC1 were 
higher in CLL patients. We also observed a negative correlation between levels of caspase-
3 and iHSPB1. An observed difference in caspase-3 levels between CLL and control 
subjects is not surprising since the underlying basis of CLL is an inability for B-
lymphocytes to commit to apoptosis. There was, however, no difference in caspase-3 
levels between patients at different stages of the disease which suggests that the 
progression of CLL is more likely to be a result of an increased cellular clonal replication 
rather than an increased resistance to apoptosis from the same cells. A more detailed 
analysis of the data has demonstrated that CLL patients in different Binet stages express 
distinct levels of iHSPC1; Levels of iHSPC1 in Binet stage A patients are significantly 
higher than levels observed in Binet stage B and C patients. This is surprising, as the anti-
apoptotic nature of these proteins would suggest they may be elevated in patients with a 
more advanced disease. However, the elevated levels of HSPC1 in patients with a less 
severe disease could be interpreted as a stress response in the early stages of the disease, 
which aids CLL cells in surviving immune destruction. As the disease progresses and CLL 
cells replicate uncontrollably, these very high HSPC1 levels are no longer required for cell 
survival and therefore begin to decrease.  
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Our data has also revealed that CLL patients can be divided into two groups based on their 
expression of iHSPA1A in CD5+/CD19+ cells; one group of patients presents very low 
levels of iHSPA1A while the other group expresses levels up to 1000-fold higher. This is also 
the case for sHSPA1A, although the difference is less pronounced. It should be noted that 
patients expressing very low levels of iHSPA1A are not necessarily the same patients that 
express low levels of sHSPA1A as no correlation between sHSPA1A and iHSPA1A could be 
found. Interestingly these CLL patients classified into the ‘low sHSPA1A or iHSPA1A 
expressing’ groups display HSPA1A levels similar to levels in non-malignant CD5-/CD19+ 
cells from the same patients and also lymphocytes from control subjects. In spite of this 
differential expression of HSPA1A amongst CLL patients, neither sHSPA1A nor iHSPA1A 
can be correlated with stage of disease or cytogenetic abnormality. Our data supports the 
work by Chant et al. (1995) who have demonstrated a wide range of HSP expression 
amongst AML patients. We have also determined that CLL patients with stable disease (not 
requiring treatment) possess significantly higher levels of iHSPA1A than patients with 
progressive disease (requiring treatment), which is in line with the decrease in HSPC1 seen 
as the disease progresses.  
There is also considerable variation in the levels of extracellular HSPA1A (eHSPA1A) 
present in the serum of CLL patients. When considered as a group, levels of eHSPA1A in 
CLL patients are not significantly different from levels in control subjects. However, a more 
detailed analysis of the data reveals a correlation between the levels of extracellular and 
intracellular HSPA1A in CLL patients. Interestingly patients receiving corticosteroid 
treatment display significantly lower levels of HSPA1A in serum when compared to 
patients not receiving corticosteroid treatment, with some steroid-treated patients showing 
near-undetectable levels of eHSPA1A. This suggests that steroid treatment may totally 
inhibit the secretion of HSPA1A, although this remains to be confirmed. However, in 
addition to their negative effects on lymphocyte proliferation, T-cell activation and NK-cell 
function, corticosteroids have been shown to regulate transcription factors. As eHSPA1A 
and iHSPA1A levels correlate and eHSPA1A levels are lower in steroid-treated patients, it 
could be deduced that the transcription of HSPA1A has been inhibited. This conclusion is 
supported by the decrease in HSPA1A release observed following commencement of 
glucocorticoid treatment in CLL patients.   
CLL patients often display resistance to corticosteroid therapy which is attributed to the 
imbalanced expression of glucocorticoid receptor (GR) isoforms. Indeed, higher 
expression of the transcriptionally inactive glucocorticoid receptor-beta (GR-beta) in 
relation to the hormone-activated transcription factor GR-alpha has been observed in 
CLL cells (Shahidi et al. 1999). However, as the GR is a client protein of HSPC1, variation 
in HSPC1 concentration may result in defective ligand binding, which may also 
contribute to resistance (Bailey et al. 2001). Indeed it has been demonstrated that the 
ratio of HSPC1 to GR expression is significantly higher in steroid-resistant compared to 
steroid-sensitive multiple sclerosis patients (Matysiak et al. 2008). This suggests that CLL 
patients in Binet stage A, whose HSPC1 expression is high, may have a reduced 
sensitivity for the steroid. 
In summary although HSPs appear to be elevated in CLL patients compared to control 
subjects, closer examination of the data reveals that this is not the case in all CLL patients 
and in fact, there is a large variability in HSPB1, HSPA1A and HSPC1 amongst patients 
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which can be associated with disease stage and also treatment regime. The results indicate 
that the concept of HSPs being over-expressed in cancer may in fact be oversimplified. 
Indeed, it is now becoming apparent that there is also great variability in HSP expression in 
solid tumours such as breast cancer (Zagouri et al. 2010). These findings are crucial in 
helping to determine whether future treatments targeting HSPs maybe considered as a 
universal option.  
7. Heat shock proteins as therapeutic targets 
Many of the most recently developed anti-cancer treatments are targeted towards a single 
specific oncoprotein. Although in many cases, this has been largely successful (Flaherty et al. 
2010; Kantarjian et al. 2003) cancer cells may acquire resistance to these treatments via a 
number of mechanisms including secondary mutations in the target binding domain and 
activation of alternative signalling pathways (Nazarian et al. 2010; Shah et al. 2002). Indeed, 
by their very nature, cancers accumulate oncogenic mutations as they progress and 
therefore a treatment strategy that involves the selective targeting of a specific protein 
kinase, for example, is unlikely to show continued success. As stated earlier, HSPs 
contribute to each of the six hallmarks of cancer and as a result have multiple molecular 
targets. In particular, HSPC1 appears to play a fundamental role in the development and 
maintenance of several tumour characteristics (Neckers, 2007). HSPC1 binds and stabilises a 
broad array of mutated oncoproteins (An et al. 2000; Minami et al. 2002; Pashtan et al. 2008), 
so the targeting of this single chaperone, should in theory, destabilise and degrade a wide 
variety of signalling kinases, therefore simultaneously targeting a number of cell signalling 
pathways. Furthermore, by selectively inhibiting HSPC1, all six ‘hallmarks of cancer’ 
(Hanahan & Weinberg, 2001; Hanahan & Weinberg, 2011) can be targeted in parallel, 
thereby dramatically reducing the probability that a resistant clone will develop. Since the 
identification of the first HSPC1 inhibitors 25 years ago, interest into these novel therapies 
has expanded considerably and the development of newer inhibitors has focussed on 
increasing efficacy and reducing side effects. Indeed a large body of data now exists 
documenting their anti-cancer effects on a wide variety of tumour cell types (Kim et al. 2009) 
both in isolation and in combination with common chemotherapeutic agents. HSPC1 
inhibitors are currently grouped according to their site of action; N-terminal inhibitors and 
C-terminal inhibitors. 
7.1 N-terminal HSPC1 inhibitors 
The original N-terminal inhibitors, geldanamycin (GA) and radicicol were naturally 
occurring antibacterial products discovered in Streptomyces hygroscopicus. Initial experiments 
using these compounds revealed binding to HSPC1 and consequent degradation of the 
HSPC1 client protein v-src (Whitesell et al. 1994). Although subsequent experiments proved 
that these natural HSPC1 inhibitors were able to cause the degradation of a wide range of 
client proteins, the non-specific toxicity of these compounds prevented their clinical use. 
However, these experiments led to the development of the first clinically applicable HSPC1 
inhibitor, 17-AAG (17-allylamino-17-demethoxygeldanamycin, also known as tanespimycin) 
(Holzbeierlein et al. 2010). As a derivative of GA, 17-AAG resulted in the degradation of a 
variety of oncogenic proteins in a number of tumour cell types, while displaying reduced 
toxicity. This compound was entered into clinical trials and tested on a broad array of 
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cancers including a large variety of haematological malignancies such as AML, ALL, CML 
and CLL. Detailed reviews of clinical trial data can be found in Kim et al. (2009), Taldone et 
al. (2008) and Holzbeierlein et al. (2010). In addition to showing initial promise as a novel 
therapy in isolation, 17-AAG also demonstrated synergism with a number of 
chemotherapeutic agents such as Bortezomib (Richardson et al. 2010), Trastuzumab (Modi et 
al. 2007) and Paclitaxel (Ramalingam et al. 2008). An alternative derivative of GA, 17-DMAG 
(17-dimethylaminoethylamino-17-demethoxygeldanamycin, also known as alvespimycin) 
was subsequently produced, with greater solubility and showed similar initial success in 
phase I and II clinical trials. Based on the results using 17-AAG and 17-DMAG, interest into 
the development of alternative HSPC1 inhibitors has increased greatly and has produced a 
number of N-terminal inhibitors including IPI-504 (Retaspimycin hydrochloride), AUY922, 
BIIB021 and SNX-2112 (Eccles et al. 2009; Hanson & Vesole, 2009; Lundgren et al. 2009; 
Okawa et al. 2008). In spite of these promising results and continuous research and 
development, clinical trials involving N-terminal inhibitors have not been without 
limitations. Hepatotoxicity and poor solubility of the drugs have been frequently reported. 
Furthermore, despite the idea of targeting the six ‘hallmarks of cancer’ through the 
inhibition of HSPC1, drug resistance has become an issue. This has been attributed to the 
increase in HSPB1 and HSPA1A following HSPC1 inhibition (Dakappagari et al. 2010; 
Ravagnan et al. 2001) due to enhanced activity of HSF-1, thereby increasing cellular 
resistance to apoptosis. This increase in HSPB1 and HSPA1A appears to be a complication 
related to the use of all N-terminal inhibitors (Taldone et al. 2008). A review by 
Holzbeierlein et al. (2010) highlights three significant clinical trials involving 17-AAG in 
which no anti-cancer response was observed and recruitment into the trials was terminated 
prematurely. Similarly, unexpected problems have been encountered using 17-DMAG. 
Another issue with HSPC1 inhibition is that, in addition to chaperoning many oncogenic 
proteins, HSPC1 also chaperones many other proteins with anti-tumour activities. The 
tumour suppressor proteins LKB1 (Boudeau et al. 2003), LATS1, LATS2 (Huntoon et al. 
2010) and wild-type p53 (Walerych et al. 2004) are all down-regulated following treatment 
with HSPC1 inhibitors. These results highlight the potential disadvantages of HSPC1 
inhibitor therapies. 
7.2 C-terminal HSPC1 inhibitors 
Research into HSPC1 inhibitors has primarily focused on N-terminal inhibition, however a 
small number of C-terminal inhibitors have been identified. Novobiocin was the first C-
terminal HSPC1 inhibitor to be identified, and similarly to GA, is a naturally occurring 
antibiotic produced in Streptomyces niveu. However, novobiocin was found to have a weak 
affinity for its target and as a result was not therapeutically applicable. Subsequently, 
research has focused on the synthesis of novobiocin analogues with a stronger affinity for 
HSPC1. According to a review by Holzbeierlein et al. (2010), over 300 analogues have been 
screened resulting in the identification of compounds with improved activity and selectivity 
of tumour over non-tumour cells. It has also been noted that the anti-cancer agent cisplatin 
and the polyphenolic flavanoid Epigallocatechin-3-gallate (EGCG) can inhibit HSPC1 
activity via C-terminal inhibition (Soti et al. 2002; Yin et al. 2009). Cisplatin has been used as 
a conventional chemotherapy for decades due to its ability to form DNA adducts and 
therefore prevent DNA transcription. By binding to the C-terminal, cisplatin hinders 
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nucleotide binding. Treatment of a human ovarian cell line with EGCG was found to inhibit 
HSPC1 activity and therefore result in the degradation of several client proteins including 
ErbB2, Raf-1, and phosphorylated Akt (Yin et al. 2009). 
C-terminal inhibitors appear to have many non-specific effects and as a result have not been 
entered into clinical trials (Sreedhar et al. 2004). However, recent research has revealed that 
C-terminal inhibition, unlike N-terminal inhibition, does not result in the enhanced activity 
of HSF-1 (Conde et al. 2009; Holzbeierlein et al. 2010). Indeed, treatment of Xenopus oocytes 
with heat shock in the presence of novobiocin results in a dose dependent decrease in HSF-1 
transcriptional activity (Conde et al. 2009). In contrast similar treatment of these cells in the 
presence of GA resulted in a dose-dependent increase in HSF-1 activity. This lack of HSF-1 
induction is a very attractive attribute of C-terminal inhibitors and therefore research and 
development into synthetic C-terminal inhibitors continues. 
7.3 Important HSPC1 client proteins in CLL 
Research into the involvement of HSPC1 in cancer progression has identified a wide variety 
of client proteins that may contribute to the progression of both solid tumours and 
haematological malignancies. There are a number of HSPC1 clients that have been 
implicated in the development and progression of CLL in particular (Johnson et al. 2007) 
and therefore the use of HSPC1 inhibitors as a treatment option appears attractive. The list 
of HSPC1 client proteins is continually expanding suggesting that novel therapeutic targets 
in CLL may present themselves in the future. 
The tyrosine kinase Zeta-associated Protein-70 (ZAP-70) is a well established poor 
prognostic factor and an HSPC1 client (Bartis et al. 2007). In normal T-cells, ZAP-70 is 
associated with the TCR where it functions in downstream TCR signalling (Cruse et al. 
2007). However, although ZAP-70 is present in normal pre-B-cells, its expression should be 
lost on maturation of the cell. Hence, the presence of ZAP-70 in CLL cells is indicative of an 
immature clone. A study by Crespo et al. (2003) found that ZAP-70 expression in CLL 
correlates with disease progression and survival, and also correlates with another well 
established CLL prognostic factor, IgVH mutational status. Castro et al. (2005) demonstrated 
that ZAP-70 in CLL cells co-immunoprecipitates with HSPC1, while ZAP-70 from normal T-
cells does not. In addition, treatment of ZAP-70+ CLL cells with HSPC1 inhibitors resulted in 
degradation of ZAP-70, while treatment of T-cells from CLL and control patients with 
HSPC1 inhibitors did not affect the expression of ZAP-70. Manipulation of ZAP-70- CLL 
cells to express ZAP-70 was shown to activate HSPC1 and induce sensitivity to 17-AAG.  
The tumour suppressor protein p53, encoded by the TP53 gene is frequently mutated in 
CLL, and other cancer types. Mutant p53+ CLL patients show increased resistance to a wide 
range of chemotherapeutic agents (Sturm et al. 2003) and therefore are often treated as a 
distinct sub-group of patients. Indeed agents that act independently of the p53 pathway, 
such as the monoclonal antibodies rituximab and alemtuzumab and other agents such as 
lenalidomide, are often used as alternative first-line treatments for patients with a 17p 
deletion (mutated p53 status). HSPC1 inhibitor treatment of CLL cells results in a dose-
dependent reduction in mutant p53 levels, a simultaneous up-regulation of wild type p53 
and consequent cytotoxicity (Lin et al. 2007). This treatment also results in an increase in 
p21, an inducer of cell cycle arrest. 
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It should be noted that this same study showed that CLL cells without a p53 mutation were 
also sensitive to HSPC1 inhibitor treatment. However, this could be due to activation of 
wild-type p53 and consequent p53-dependent apoptosis. Further research has shown a 
synergistic effect between 17-DMAG and Doxorubicin, demonstrating a sensitisation of p53 
mutated cells to Doxorubicin-induced cell death (Robles et al. 2006).  
HSPC1 chaperones a broad array of protein kinases involved in signal transduction 
pathways including phosphorylated Akt, Lyn, B-Raf and IκK (Broemer et al. 2004; da 
Rocha Dias et al. 2005; Sato et al. 2000; Trentin et al. 2011). The interaction of HSPC1 with 
these phosphorylated kinases prevents dephosphorylation of the kinase and its 
subsequent inactivation, therefore maintaining its activity. The over-activity of Akt 
(Ringshausen et al. 2002), Lyn (Contri et al. 2005), and implied elevation of IκK (Hertlein 
et al. 2010) in CLL cells has been previously observed and thought to contribute to cell 
survival and activation of downstream kinases. Indeed, as IκK regulates the activation of 
the NF-κB family of transcription factors, its over-activity has implications for a large 
number of NF-κB target genes including Bcl-2, X-IAP, c-FLIP and Mcl-1 (Hertlein et al. 
2010). In fact, a number of these proteins have been implicated in the progression of CLL 
and have been found to correlate with poor prognosis (Pepper et al. 2008; Pepper et al. 
2009) which may suggest a clear link to over-activity of NF-κB. Nevertheless,  HSPC1 
inhibitor treatment has been shown to destabilise Akt, Lyn and IκK (Hertlein et al. 2010; 
Johnson et al. 2007; Jones et al. 2004; Lin et al. 2007; Trentin et al. 2008), in CLL cells 
resulting in proteosomal degradation of these HSPC1 clients and ultimately apoptosis. A 
study by McCraig et al. (2011) showed that CD40 stimulation of CLL cells in-vitro 
increased the expression of the anti-apoptotic protein Mcl-1 and enhanced cell survival, 
suggesting that Mcl-1 may be responsible for in-vivo survival of CLL cells following CD40 
stimulation by T-cells. 17-DMAG treatment of CLL cells was found to result in down-
regulation of Mcl-1 even in the presence of CD40 stimulation and inhibit in-vitro survival 
(Hertlein et al. 2010; McCraig et al. 2011) suggesting that in-vivo treatment with 17-DMAG 
may prevent CLL survival associated with T-cell stimulation in lymph nodes. 
The B-cell restricted enzyme, Activation-Induced Cytidine Deaminase (AID) has been 
shown to have prognostic significance in CLL (Heintel et al. 2004; Palacios et al. 2010). This 
enzyme is required in normal B-cells for somatic hypermutation and class switch 
recombination (CSR) and is induced following interaction of CD40 with CD40L on T-cells in 
germinal centres. However, AID expression has been found in CLL cells circulating in 
peripheral blood and has been found to correlate with unmutated IgVH status and 
unfavourable cytogenetics (Heintel et al. 2004). AID expressing CLL cells were also shown 
to expresses high levels of anti-apoptotic proteins and proliferation factors (Palacios et al. 
2010). It was proposed that these high levels of AID and ongoing CSR are a consequence of 
recent contact with the proliferation centres and provides further evidence that the 
microenvironment plays a critical role in CLL cell survival and disease progression. 
Interestingly, AID is an HSPC1 client and chemical inhibition of HSPC1 activity results in 
destabilisation and proteosomal degradation of AID and reduced antibody diversification 
(Orthwein et al. 2010).  
It would appear that HSPC1 inhibitor treatment of CLL cells targets a wide variety of client 
proteins, many of which have been implicated in the progression of the disease. 
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Furthermore, HSPC1 inhibitor-induced cell death appears to be p53 independent suggesting 
that it may also be useful in the treatment of patients with a mutated p53 status. However, it 
is well established that CLL has an extremely heterogeneous clinical course and as a result 
patients show great variation in their responses to specific treatments. Results from our lab 
have shown that CLL patients also show great heterogeneity in HSP levels with some 
patients expressing very high levels of a particular HSP and some patients expressing 
extremely low levels (Dempsey et al. 2010a). These results indicate that although targeting 
HSPs may appear an attractive strategy, it may not be successful in all patients. Therefore, 
HSP analysis may prove useful in providing a personalised treatment.  
7.4 Effect of HSPC1 inhibition on normal cells 
As HSPC1 is abundant in non-tumour cells, the use of HSPC1 inhibitors as anti-cancer 
therapies may seem impractical. Indeed, the survival of normal cells following exposure to 
stressors such as ionising radiation or cytotoxic drugs is dependent upon activation of signal 
transduction pathways, the components of which are HSPC1 client proteins. This is 
important as in the clinical setting, both tumour and non-tumour cells may have been pre-
exposed to cytotoxic drugs or ionising radiation as part of previous therapy. Little is known 
about the effects of HSPC1 inhibition on signal transduction pathways in stressed non-
tumour cells and whether the response to HSPC1 inhibitors depends upon the pre-existing 
levels of HSPA1A and HSPB1 in target cells. Although HSPC1 inhibitors have been shown 
to be highly tumour-specific, this has recently been questioned (Gooljarsingh et al. 2006). If 
correct, introduction of these inhibitors into the systemic circulation, where they will have 
access to both tumour and non-tumour cells, may introduce complications and this issue 
warrants further investigation. 
7.5 Targeting HSPA1A 
At present, the modulation of HSPA1A activity using chemical inhibitors does not appear to 
be achievable in the clinical setting. Although, several compounds are able to inhibit the 
activity of HSF-1 and therefore regulate HSPA1A, the associated toxicity with HSF-1 and 
HSPA1A inhibitors is too severe. Furthermore, the inhibition of HSF-1 appears to have a 
number of associated effects such as the up-regulation of Hsp32, which itself is anti-
apoptotic (Lin et al. 2004; Yao et al. 2007). The flavanoid quercetin and the benzylidene 
lactam KNK-437 have both been shown to inhibit HSPA1A and HSPB1 and sensitise cells to 
chemotherapeutic drugs or hyperthermia (Taba et al. 2011; Sahin et al. 2011; Zanini et al. 
2007). Furthermore, the ability of KNK-437 to enhance the anti-tumour activity of HSPC1 
inhibitors has been demonstrated (Guo et al. 2005), although as yet, this has not been tested 
on primary cells. These data suggest that if the solubility issues and non-specific effects of 
these inhibitors can be resolved, HSF-1 and/or HSPA1A may prove effective therapeutic 
targets. Recent work by Zaarur et al. (2006) used a high throughput screening programme to 
identify chemicals with the capacity to inhibit the heat shock response. Although a number 
of compounds were identified, one in particular, Emunin, showed very low levels of toxicity 
while sensitising cells to HSPC1 inhibitors and proteosome inhibitors. Interestingly, this 
compound appeared to have a novel mode of action as it did not affect HSF-1 activity. 
Although its exact mechanism remains to be determined, it appears to possess a specific 
regulatory affect on HSP protein translation. A further benefit of using this type of 
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compound is that if, as in some cases, the over-expression of HSPs in a tumour is HSF-1 
independent (Zaarur et al. 2006), manipulating the stress response in this way may still 
prove advantageous. 
The surface expression of HSPA1A on tumour cells provides a novel focus for anti-cancer 
therapies. The ability of membrane embedded HSPA1A to bind and stimulate NK-cells and 
induce killing of sHSPA1A+ tumour cells (Gross et al. 2003; Gross et al. 2008; Multhoff et al. 
1999) has led to trials involving ex-vivo stimulation of autologous NK-cells with TKD 
peptide and low dose IL-2. This patient-specific technique involves obtaining leukocyte 
concentrates from the patient by leukapheresis, purifying PBMCs and stimulating them 
with TKD peptide/low dose IL-2 for four days. Following stimulation, the activated PBMC 
preparation is re-infused into the patient. Re-infusion is repeated every fortnight for a 
maximum of five doses (Krause et al. 2004). This technique has been shown to eliminate the 
primary tumour, prevent metastasis and significantly increase life expectancy in tumour 
mouse models (Mutlhoff et al. 2000; Stangl et al. 2006). Furthermore, use of this technique in 
patients with lower rectal carcinoma and non-small cell lung carcinoma was found to 
increase NK-cell cytotoxicity against sHSPA1A+ tumour cells (Krause et al. 2004) and was 
found to be well tolerated. However, it should be noted that patients included in this study 
did not show complete remission following treatment but these were patients with 
advanced disease and were refractory to standard chemotherapy. A subsequent case study 
using another advanced disease patient was unsuccessful in attaining remission, but did 
demonstrate the maintenance of NK-cell cytolytic activity following TKD-IL-2 stimulation 
(Milani et al. 2009). These data suggest that ex-vivo TKD/IL-2 stimulation of autologous NK-
cells may have therapeutic potential. 
As an alternative strategy to inhibiting the activity of HSPs, recent work from our lab 
attempted to manipulate the cellular location of HSPs in order to sensitise CLL cells to 
chemotherapeutic agents (Dempsey et al. 2010b). As mentioned earlier, a number of HSPs 
associate with lipid rafts and incorporate into the plasma membrane (Gastpar et al. 2005; 
Nagy et al. 2007; Vega et al. 2008) where they may remain or may be released into the 
extracellular environment. Vigh et al. (2007b) have proposed a ‘membrane sensor model’ in 
which cell stress may be detected at the membrane level and the cell is able to produce a 
stress response. It is proposed that stress signals originating from the cell membrane result 
in activation of specific HSP genes and movement of these newly synthesised HSPs to the 
membrane where they facilitate in stabilising the cell membrane (Vigh et al. 2007a) and 
therefore facilitating cell survival (Figure 2). It is proposed that a change in membrane 
fluidity and microdomain organisation (Torok et al. 2003; Vigh et al. 2007a) may be 
sufficient to result in such membrane stress signals. Our group used several membrane 
fluidising treatments including aliphatic alcohol, local anaesthetic or mild hyperthermia to 
fluidise the cell membrane and induce movement of HSPs to the cell surface (Dempsey et al. 
2010b). The result was a change in the cellular localisation of HSPA1A, HSPD1, and to a 
lesser extent, HSPB1 and HSPC1. We found that this movement to the cell surface resulted 
in a transient decrease in internal levels of HSPs. This temporary decrease in anti-apoptotic 
HSPs allowed a number of chemotherapeutic agents including Doxorubicin, 
Cyclophosphamide and TRAIL to act on the cells resulting in significant cytotoxicity of CLL 
cells. Interestingly, by combining membrane fluidising treatments with chemotherapeutic 
agents, low doses of drugs were able to cause considerable apoptosis. These low doses were 
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unable to cause cytotoxicity in isolation. We found that inhibiting the movement of HSPs 
using methyl-ǃ-cyclodextrin (mǃcd), a cholesterol sequestering agent, and inhibitor of lipid 
raft transport, prior to combination treatment, prevented the synergistic effect of fluidising 
treatment and chemotherapeutic drug. The results suggest that manipulation of HSP 
cellular location may be an attractive strategy for enhancing the chemotherapeutic treatment 
of CLL. Furthermore, this method does not rely on CLL patients expressing similar levels of 
internal HSPs and therefore is an attractive therapeutic approach for a heterogeneous 
disease. Furthermore, the data may point to a revival of targeted hyperthermia to induce 
HSP translocation in combination with other therapeutic agents.  
 
Fig. 2. Induction of an HSP Response via Alteration in Membrane Fluidity (Taken from 
Dempsey, 2009). Change in membrane fluidity is detected at the membrane, activating a 
membrane signal which results in the transcription of HSP genes. Newly synthesised HSPs 
then move to the membrane resulting in membrane stabilisation and re-established 
membrane-lipid order. This stabilisation effect may itself be a negative feedback regulator to 
turn off HSP transcription.  
8. Conclusion 
The up-regulation of HSPs in cancer has led to a large variety of studies investigating their 
prognostic and therapeutic potential. Due to the stressful nature of tumour development, it 
is not surprising that these anti-apoptotic proteins remain elevated in cancer cells. The anti-
apoptotic characteristics of these proteins enable tumour cells to survive in otherwise lethal 
conditions and hence have been associated with a poor prognosis and resistance to therapy. 
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These elements alone suggest HSPs may be suitable targets for therapy. However after 
considering that a number of HSPs are involved in the modifications required for cancer 
development (the six ‘hallmarks of cancer’), they become particularly attractive. Further 
work on inhibiting HSP activity is required before such compounds can be considered as 
routine therapies. Extracellular HSPs have been shown to have critical roles in cancer 
progression with surface-bound HSPC1 in particular contributing to cell invasion and 
metastasis. Conversely, sHSPA1A has been shown to be detrimental to the tumour, 
stimulating NK-cell responses and resulting in tumour regression, while a number of 
extracellular HSPs present tumour-derived peptides to APCs resulting in antigen cross-
presentation and T-cell responses. The beneficial effects of these extracellular HSPs have 
also formed the basis of research into HSP-based therapies focusing on increasing the 
immune response against tumours. Increasing HSP translocation via cell membrane 
fluidisation may therefore have the double benefit of increasing the susceptibility of 
tumours to chemotherapeutic agents and stimulating the immune response. Our work on 
CLL has found that HSPA1A, HSPB1 and HSPC1 are located inside CLL cells, on the cell 
surface and also in the serum of CLL patients. However, the pattern of patient variability 
within and between specific HSPs suggests that analysis of patient HSP profile would be 
beneficial in directing therapy.  
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